Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 372

1.

Pathway analysis for design of promiscuous drugs and selective drug mixtures.

Sivachenko A, Kalinin A, Yuryev A.

Curr Drug Discov Technol. 2006 Dec;3(4):269-77. Review.

PMID:
17430103
2.

From drug target to leads--sketching a physicochemical pathway for lead molecule design in silico.

Shaikh SA, Jain T, Sandhu G, Latha N, Jayaram B.

Curr Pharm Des. 2007;13(34):3454-70. Review.

PMID:
18220783
3.

Competitive Workflow: novel software architecture for automating drug design.

Cartmell J, Krstajic D, Leahy DE.

Curr Opin Drug Discov Devel. 2007 May;10(3):347-52. Review.

PMID:
17554862
4.

Leadlikeness and structural diversity of synthetic screening libraries.

Verheij HJ.

Mol Divers. 2006 Aug;10(3):377-88. Epub 2006 Sep 21.

PMID:
17031539
5.

Can we rationally design promiscuous drugs?

Hopkins AL, Mason JS, Overington JP.

Curr Opin Struct Biol. 2006 Feb;16(1):127-36. Epub 2006 Jan 25. Review.

PMID:
16442279
6.

Pathway analysis software as a tool for drug target selection, prioritization and validation of drug mechanism.

Sivachenko AY, Yuryev A.

Expert Opin Ther Targets. 2007 Mar;11(3):411-21. Review.

PMID:
17298298
7.

Predictive QSAR modeling workflow, model applicability domains, and virtual screening.

Tropsha A, Golbraikh A.

Curr Pharm Des. 2007;13(34):3494-504. Review.

PMID:
18220786
8.

Ranking poses in structure-based lead discovery and optimization: current trends in scoring function development.

Rajamani R, Good AC.

Curr Opin Drug Discov Devel. 2007 May;10(3):308-15. Review.

PMID:
17554857
9.

Physics-based methods for studying protein-ligand interactions.

Huang N, Jacobson MP.

Curr Opin Drug Discov Devel. 2007 May;10(3):325-31. Review.

PMID:
17554859
10.

Importance of molecular computer modeling in anticancer drug development.

Geromichalos GD.

J BUON. 2007 Sep;12 Suppl 1:S101-18. Review.

PMID:
17935268
11.
12.

Recent developments in de novo design and scaffold hopping.

Mauser H, Guba W.

Curr Opin Drug Discov Devel. 2008 May;11(3):365-74. Review.

PMID:
18428090
13.

Proteomics approach to illustrate drug action mechanisms.

Wang Y, Chiu JF, He QY.

Curr Drug Discov Technol. 2006 Sep;3(3):199-209. Review.

PMID:
17311565
14.

Drug discovery beyond the 'rule-of-five'.

Zhang MQ, Wilkinson B.

Curr Opin Biotechnol. 2007 Dec;18(6):478-88. Epub 2007 Nov 26. Review.

PMID:
18035532
15.

Identification of drugs that interact with herbs in drug development.

Zhou SF, Zhou ZW, Li CG, Chen X, Yu X, Xue CC, Herington A.

Drug Discov Today. 2007 Aug;12(15-16):664-73. Epub 2007 Jul 30. Review.

PMID:
17706549
16.
17.

Physiologically based modelling and prediction of drug interactions.

Bois FY.

Basic Clin Pharmacol Toxicol. 2010 Mar;106(3):154-61. doi: 10.1111/j.1742-7843.2009.00488.x. Epub 2009 Nov 11. Review.

18.

Recent advances in computer-aided drug design.

Song CM, Lim SJ, Tong JC.

Brief Bioinform. 2009 Sep;10(5):579-91. doi: 10.1093/bib/bbp023. Epub 2009 May 11. Review.

PMID:
19433475
19.

Early prediction of drug metabolism and toxicity: systems biology approach and modeling.

Bugrim A, Nikolskaya T, Nikolsky Y.

Drug Discov Today. 2004 Feb 1;9(3):127-35. Review.

PMID:
14960390
20.

Topological approach to drug design.

Gálvez J, García-Domenech R, de Julián-Ortiz JV, Soler R.

J Chem Inf Comput Sci. 1995 Mar-Apr;35(2):272-84. Erratum in: J Chem Inf Comput Sci 1995 Sep-Oct;35(5):938.

PMID:
7730417

Supplemental Content

Support Center